Skip to main content
SAREUM HOLDINGS PLC logo

SAREUM HOLDINGS PLC — Investor Relations & Filings

Ticker · SAR ISIN · GB00BMC3RJ87 LEI · 213800PKERN2DY8FFM72 IL Manufacturing
Open in API
Filings indexed 348 across all filing types
Latest filing 2025-08-26 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL SAR

About SAREUM HOLDINGS PLC

https://www.sareum.com/

Sareum Holdings PLC is a clinical-stage small molecule company that discovers and develops next-generation kinase inhibitors for the treatment of autoimmune diseases and cancer. The company's research is primarily focused on the TYK/JAK kinase cell signalling family, with a specific emphasis on developing dual inhibitors of TYK2 and JAK1. This approach is pursued for its potential to offer superior efficacy compared to agents that target only one of these kinases. Its development pipeline includes SDC-1801, a potential oral therapy for autoimmune diseases, as well as other programs targeting cancer and viral infections.

Recent filings

Filing Released Lang Actions
Exercise of Warrants
Share Issue/Capital Change Classification · 100% confidence The document is an RNS announcement from Sareum Holdings plc regarding the exercise of warrants and the subsequent issuance of new ordinary shares. This falls under the category of capital changes and share issuance. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the most accurate classification for announcements regarding new share issues resulting from warrant exercises.
2025-08-26 English
Exercise of Warrants
Share Issue/Capital Change Classification · 100% confidence The document is an RNS announcement regarding the exercise of warrants and the subsequent issuance of new ordinary shares. This falls under the category of share capital changes or new share issues. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the most accurate classification for announcements regarding new share issues.
2025-08-20 English
Sareum Collaboration with Receptor.AI
Regulatory Filings Classification · 100% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) announcing a strategic collaboration between Sareum Holdings PLC and Receptor.AI. It details the nature of the partnership, the goals of the research, and provides contact information. Since it is a general corporate announcement regarding business operations and partnerships that does not fit into specific categories like financial reports, dividends, or director dealings, it is classified as a Regulatory Filing (RNS).
2025-08-12 English
Exercise of Warrants
Share Issue/Capital Change Classification · 99% confidence The document is identified by the RNS Number (2586Q) and the header 'National Storage Mechanism | Additional information'. The content details the 'Exercise of Warrants' resulting in the issuance of 1,000,000 new ordinary shares and subsequent update to the Total Voting Rights. This type of announcement, which concerns capital structure changes (share issuance via warrant exercise) and is distributed via the London Stock Exchange's RNS system, fits best under the general 'Regulatory Filings' category, as there is no specific code for warrant exercises or general capital changes that aren't a formal share issue announcement (SHA) or buyback (POS). Since it is a formal regulatory announcement distributed via RNS, and it doesn't fit the specific definitions of CAP (financing activity) or SHA (new share issue, though this is related), RNS is the most appropriate fallback for a standard regulatory news service release.
2025-07-09 English
Appointment of Sole Broker
Regulatory Filings Classification · 98% confidence The document is a short regulatory announcement (RNS) regarding the appointment of a new sole broker (Oberon Capital) for Sareum Holdings PLC. Since this is a corporate announcement regarding a change in service providers/advisors and does not fit into specific categories like M&A, Board changes, or financial reporting, it falls under the general regulatory filing category.
2025-07-04 English
Initiation of Toxicology Studies for SDC-1801
Regulatory Filings Classification · 99% confidence The document is identified by the header 'RNS Number' and contains a standard closing statement referencing 'RNS, the news service of the London Stock Exchange' and the FCA. The content announces a specific corporate event: the initiation of toxicology studies for a drug candidate (SDC-1801), which is a material operational update for a clinical-stage biotechnology company. This type of announcement, distributed via the London Stock Exchange's regulatory news service (RNS) and not fitting into specific financial report categories (like 10-K, ER, IR), falls best under the general regulatory announcement category.
2025-05-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.